# Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

> **NCT07025538** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 42 (estimated)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm

## Interventions

- **OTHER:** Best Practice
- **OTHER:** Biomarker Analysis
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Questionnaire Administration
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07025538
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-06-22
- **Final completion:** 2028-06-22
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07025538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07025538, "Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07025538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*